Memantine Should Be Administered Twice Daily, Not Only at Night
Memantine must be dosed twice daily (BID) at the target dose of 20 mg/day (10 mg twice daily), not as a single nighttime dose. The FDA-approved dosing regimen is explicitly 5 mL (10 mg) twice daily for the standard immediate-release formulation 1.
FDA-Approved Dosing Schedule
The prescribing information is unambiguous about the dosing regimen 1:
- Starting dose: 5 mg once daily
- Titration: Increase by 5 mg increments weekly to reach:
- Week 2: 5 mg twice daily (10 mg/day total)
- Week 3: 10 mg morning + 5 mg evening (15 mg/day total)
- Week 4+: 10 mg twice daily (20 mg/day total - target dose)
The effective dose demonstrated in clinical trials is 20 mg/day given as 10 mg twice daily 1. This twice-daily dosing is not arbitrary—it reflects the pharmacokinetic profile needed to maintain therapeutic drug levels.
Why Twice-Daily Dosing Matters
The immediate-release formulation requires BID dosing to maintain stable plasma concentrations throughout the day. Giving the entire 20 mg dose at night would create inappropriately high peak levels followed by subtherapeutic troughs, potentially compromising both efficacy and tolerability.
The evidence base supporting memantine's efficacy in moderate-to-severe Alzheimer's disease used twice-daily dosing 2, 3. High-certainty evidence shows small but consistent clinical benefits across cognition (3.11 SIB points), global function (0.21 CIBIC+ points), activities of daily living (1.09 ADL19 points), and behavior (1.84 NPI points) with the standard BID regimen 4.
Once-Daily Alternative: Extended-Release Formulation
If once-daily dosing is desired for adherence reasons, an extended-release formulation (28 mg once daily) exists specifically for this purpose 5, 6. This formulation was developed to improve medication adherence while maintaining therapeutic levels. However, even this higher-dose extended-release version showed similar efficacy to the standard BID regimen, not superior outcomes 7.
The extended-release 28 mg once-daily formulation can be taken at any time of day (not specifically at night), with or without food 5.
Clinical Pitfalls to Avoid
- Do not consolidate the 20 mg immediate-release dose into a single nighttime administration—this is not supported by pharmacokinetic data or clinical trials
- Do not skip the titration schedule—rapid dose escalation increases adverse events (dizziness, headache) 1
- If a patient misses several doses, restart at lower doses and retitrate 1
- In severe renal impairment (CrCl 5-29 mL/min), reduce target dose to 5 mg twice daily 1
Bottom Line
For standard immediate-release memantine in moderate-to-severe Alzheimer's disease, prescribe 10 mg twice daily (morning and evening) after appropriate weekly titration from 5 mg once daily. If once-daily dosing is clinically necessary for adherence, switch to the extended-release 28 mg formulation rather than inappropriately modifying the immediate-release dosing schedule.